Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients
Status:
Completed
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
The current standard of catecholamine vasopressor management of perioperative hypotension in
kidney transplant patients carries significant risks and falls short in many ways. Currently,
there is an absence in the scientific literature and research describing the hemodynamic
effectiveness and safety of novel pharmacologic agents such as angiotensin II (Giapreza - Ang
II) in perioperative kidney transplant patients. Phase 3 registration trials have
demonstrated the superior safety and efficacy of Ang II (Giapreza) in distributive shock
patients compared to traditional vasopressor agents and the novel mechanism of action may
provide additional protection in renal transplant patients. The pilot study entails giving
informed and consenting kidney transplant recipients Ang II (Giapreza) as their first
vasopressor if the need for vasopressors emerge either intraoperatively or postoperatively in
kidney transplant recipients. The primary objective is to evaluate the safety and hemodynamic
effects of Ang II (Giapreza) in the renal transplant population.